Currently, MGTX's current EPS stands at $0.76, according to the most recent financial reports. For the year 2025, MGTX reported a per-share earnings of -$1.42, which marks an increase compared to the EPS of -$2.12 recorded in 2024. MGTX recorded an EPS of $1.76 for the quarterly period ending on Jun 30, 2026.
In 2025, MeiraGTx Holdings's EPS was -$1.42, an increase of 33% from -$2.12 in 2024. For the fiscal quarter that ended on Jun 30, 2026, the per-share earnings was $1.76, reflecting a 466.7% increase compared to the same quarter a year earlier. For the twelve months ending June 2026, the EPS is $0.76. For the year 2024, the yearly earnings per share was -$2.12, marking a decrease of 42.3% compared to 2023.
MeiraGTx Holdings has registered a growth in earnings per share of 466.7% over the past 12 months (YoY, quarterly).
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| ORMP Oramed Pharmaceuticals Inc | 1.12 | 418.8% | N/A | N/A |
| MGTX MeiraGTx Holdings plc | 15.46 | 33% | N/A | N/A |
| NVAX Novavax Inc | N/A | 321.1% | N/A | N/A |
| NVCR NovoCure Ltd | N/A | 21.8% | N/A | N/A |
| VIVS VivoSim Labs Inc. | N/A | -214.7% | N/A | N/A |
| ORIC Oric Pharmaceuticals Inc | N/A | 19.7% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.